NEW YORK (GenomeWeb News) — Caliper Life Sciences said today it expects its fourth-quarter 2008 revenues to be $36.5 million, near the upper end of its previous guidance for the quarter of $34 million to $37 million, but 9 percent lower than revenues for the year-ago quarter of $40.3 million.
The company said that it expects to post $133.9 million in full-year 2008 revenue, approximately 5 percent lower than its full-year 2007 revenues of $140.7 million.
During the fourth quarter, Caliper sold its Pharmaceutical Development & Quality and AutoTrace product lines for a total of around $21 million. The company said today that 2008 pro forma revenue, which reflects the divestiture of those product lines, is expected to be approximately $34.6 million for the fourth quarter and $122.8 million for the full year.
For 2009, Caliper currently expects total revenue to increase around 4 percent to 7 percent over 2008 pro forma revenue, with the growth primarily occurring in the second half of the year. In its preliminary revenue statement, the company cited "currency headwinds" as a key factor for its estimates.
The company noted that these financial results are preliminary and are subject to change.